Gene Transfer Approaches for Gynecological Diseases

Molecular Therapy

Volumn 14, Issue 2, 2006, Pages 154-163

  Raki, Mari ^a,b   Rein, Daniel T ^c   Kanerva, Anna ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

cervical cancer; gene therapy; gene transfer; gynecological disease; ovarian cancer

Indexed keywords

ACICLOVIR; AD21; ADVEXIN; ALPHA INTERFERON; ANGIOSTATIN; ANTIBODY; BETA GALACTOSIDASE; BRCA1 PROTEIN; DCC E1A; E1A PROTEIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 INTRABODY; GANCICLOVIR; INTERLEUKIN 24; LIPOSOME; MIDKINE; ONCOLYTIC VIRUS; ONYX 015; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN P73; SOMATOMEDIN B; SOMATOMEDIN C; THYMIDINE KINASE; TOPOTECAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA10; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VIRUS VECTOR;

ADENOVIRUS; CLINICAL TRIAL; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GYNECOLOGIC CANCER; GYNECOLOGIC DISEASE; HUMAN; NONHUMAN; OVARY CANCER; REVIEW; SUICIDE GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS; FEMALE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; RECEPTORS, GROWTH FACTOR; RECEPTORS, VIRUS;

EID: 33745418301     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.02.019     Document Type: Review

References (112)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Kanerva A., and Hemminki A. Adenoviruses for treatment of cancer. Ann. Med. 37 (2005) 33-43
3. Rancourt C., et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4 (1998) 2455-2461
4. Kelly F.J., et al. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin. Cancer Res. 6 (2000) 4323-4333
5. Hakkarainen T., et al. CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin. Cancer Res. 9 (2003) 619-624
6. Vanderkwaak T.J., et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. 74 (1999) 227-234
7. Kanerva A., et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8 (2002) 275-280
8. Kanerva A., et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5 (2002) 695-704
9. Buller R.E., et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9 (2002) 553-566
10. Hasenburg A., et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther. 7 (2000) 839-844
11. Raper S.E., et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80 (2003) 148-158
12. Chung I., Schwartz P.E., Crystal R.G., Pizzorno G., Leavitt J., and Deisseroth A.B. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther. 6 (1999) 99-106
13. Casado E., et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin. Cancer Res. 7 (2001) 2496-2504
14. Bao R., Selvakumaran M., and Hamilton T.C. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol. Oncol. 84 (2002) 228-234
15. Barker S.D., et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J. Gene Med. 5 (2003) 300-310
16. Barker S.D., et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther. 10 (2003) 1198-1204
17. Breidenbach M., et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 12 (2005) 187-193
18. Shahin M.S., Hughes J.H., Sood A.K., and Buller R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89 (2000) 2006-2017
19. Santoso J.T., et al. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol. Oncol. 59 (1995) 171-178
20. Mujoo K., Maneval D.C., Anderson S.C., and Gutterman J.U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12 (1996) 1617-1623
21. Kim C.K., Choi E.J., Choi S.H., Park J.S., Haider K.H., and Ahn W.S. Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC. Gynecol. Oncol. 90 (2003) 265-272
22. Buller R.E., et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 9 (2002) 567-572
23. Wolf J.K., et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol. Oncol. 94 (2004) 442-448
24. Wen S.F., et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 10 (2003) 224-238
25. Zeimet A.G., and Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol. 4 (2003) 415-422
26. Tait D.L., et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin. Cancer Res. 3 (1997) 1959-1968
27. Tait D.L., Obermiller P.S., Hatmaker A.R., Redlin-Frazier S., and Holt J.T. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. 5 (1999) 1708-1714
28. Deshane J., Loechel F., Conry R.M., Siegal G.P., King C.R., and Curiel D.T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther. 1 (1994) 332-337
29. Slamon D.J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
30. Deshane J., et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol. Oncol. 59 (1995) 8-14
31. Deshane J., et al. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96 (1995) 2980-2989
32. Deshane J., Grim J., Loechel S., Siegal G.P., Alvarez R.D., and Curiel D.T. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther. 3 (1996) 89-98
33. Alvarez R.D., et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6 (2000) 3081-3087
34. Yu D., Matin A., Xia W., Sorgi F., Huang L., and Hung M.C. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 11 (1995) 1383-1388
35. Hortobagyi G.N., et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J. Clin. Oncol. 19 (2001) 3422-3433
36. Madhusudan S., et al. A multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin. Cancer Res. 10 (2004) 2986-2996
37. Rosenfeld M.E., Feng M., Michael S.I., Siegal G.P., Alvarez R.D., and Curiel D.T. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res. 1 (1995) 1571-1580
38. Tong X.W., et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol. Oncol. 61 (1996) 175-179
39. Alvarez R.D., et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther. 2 (2000) 524-530
40. Hasenburg A., et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol. 83 (2001) 549-554
41. Hemminki A., et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol. Ther. 4 (2001) 223-231
42. Hemminki A., et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J. Natl. Cancer Inst. 94 (2002) 741-749
43. Boocock C.A., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. 87 (1995) 506-516
44. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255 (1992) 989-991
45. Mahasreshti P.J. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. 7 (2001) 2057-2066
46. Mahasreshti P.J., et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res. 9 (2003) 2701-2710
47. Mahendra G., et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 12 (2005) 26-34
48. Subramanian I.V., Ghebre R., and Ramakrishnan S. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther. 12 (2005) 30-38
49. Indraccolo S., et al. Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum. Gene Ther. 16 (2005) 957-970
50. Sinkovics J., and Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology 36 (1993) 193-214
51. Lamfers M.L., and Hemminki A. Multicellular tumor spheroids in gene therapy and oncolytic virus therapy. Curr. Opin. Mol. Ther. 6 (2004) 403-411
52. Bauerschmitz G.J., et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62 (2002) 1266-1270
53. Lam J.T., et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther. 10 (2003) 377-387
54. Lam J.T., et al. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J. Gene Med. 6 (2004) 1333-1342
55. Kanerva A., et al. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. 11 (2004) 552-559
56. Kirn D., Martuza R.L., and Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7 (2001) 781-787
57. Xia Z.J., et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23 (2004) 1666-1670
58. Alemany R., Balague C., and Curiel D.T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18 (2000) 723-727
59. Bischoff J.R., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
60. Vasey P.A., et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20 (2002) 1562-1569
61. Kanerva A., et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. 8 (2003) 449-458
62. Saukkonen K., and Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther. 4 (2004) 683-696
63. Hamada K., et al. Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res. 63 (2003) 2506-2512
64. Rein D.T., et al. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin. Cancer Res. 11 (2005) 1327-1335
65. Rein D.T., and Kurbacher C.M. The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anticancer Drugs 12 (2001) 787-795
66. Carson A., Wang Z., Xiao X., and Khan S.A. A DNA recombination-based approach to eliminate papillomavirus infection. Gene Ther. 12 (2005) 534-540
67. Bauerschmitz G.J., et al. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int. J. Cancer 111 (2004) 303-309
68. Balague C., Noya F., Alemany R., Chow L.T., and Curiel D.T. Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J. Virol. 75 (2001) 7602-7611
69. Das S., El-Deiry W.S., and Somasundaram K. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. Oncogene 22 (2003) 8394-8402
70. Boyd J. Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes. Gynecol. Oncol. 61 (1996) 163-165
71. Ramondetta L., Mills G.B., Burke T.W., and Wolf J.K. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin. Cancer Res. 6 (2000) 278-284
72. Grundker C., Huschmand Nia A., and Emons G. Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers. Mol. Cancer. Ther. 4 (2005) 225-231
73. Edmonds K. Dewhurst's Textbook of Obstetrics and Gynaecology for Postgraduates (1999), Blackwell Sci, Oxford, UK
74. Niu H., Simari R.D., Zimmermann E.M., and Christman G.M. Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells. Obstet. Gynecol. 91 (1998) 735-740
75. Al-Hendy A., Lee E.J., Wang H.Q., and Copland J.A. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am. J. Obstet. Gynecol. 191 (2004) 1621-1631
76. Dabrosin C., Gyorffy S., Margetts P., Ross C., and Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am. J. Pathol. 161 (2002) 909-918
77. Fortin M., et al. Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis. Mol. Ther. 9 (2004) 540-547
78. Levine R.J., et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350 (2004) 672-683
79. Senut M.C., Suhr S.T., and Gage F.H. Gene transfer to the rodent placenta in situ: a new strategy for delivering gene products to the fetus. J. Clin. Invest. 101 (1998) 1565-1571
80. Heikkila A., et al. Angiographically guided utero-placental gene transfer in rabbits with adenoviruses, plasmid/liposomes and plasmid/polyethyleneimine complexes. Gene Ther. 8 (2001) 784-788
81. Miller A.G., Aplin J.D., and Westwood M. Adenovirally mediated expression of insulin-like growth factors enhances the function of first trimester placental fibroblasts. J. Clin. Endocrinol. Metab. 90 (2005) 379-385
82. Eun Kwon H., and Taylor H.S. The role of HOX genes in human implantation. Ann. N. Y. Acad. Sci. 1034 (2004) 1-18
83. Bagot C.N., Troy P.J., and Taylor H.S. Alteration of maternal Hoxa10 expression by in vivo gene transfection affects implantation. Gene Ther. 7 (2000) 1378-1384
84. Immonen A., et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10 (2004) 967-972
85. Puumalainen A.M., et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 9 (1998) 1769-1774
86. Kanerva A., et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther. 12 (2005) 87-94
87. Le L.P., Everts M., Dmitriev I.P., Davydova J.G., Yamamoto M., and Curiel D.T. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol. Imaging 3 (2004) 105-116
88. Kanerva A., and Hemminki A. Modified adenoviruses for cancer gene therapy. Int. J. Cancer 110 (2004) 475-480
89. Hermiston T.W., and Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 9 (2002) 1022-1035
90. Khuri F.R., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6 (2000) 879-885
91. Peng Z., et al. Clinical evaluation of safety and efficacy of intratumoral administration of a recombinant adenoviral-p53 anticancer agent (Genkaxin). Mol Ther. 7 (2003) S422-S423 (Abstract)
92. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16 (2005) 1016-1027
93. Lu W., Zheng S., Li X.F., Huang J.J., Zheng X., and Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J. Gastroenterol. 10 (2004) 3634-3638
94. Raki M., et al. Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther. 12 (2005) 1198-1205
95. Mastrangeli A., et al. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7 (1996) 79-87
96. Christ M., et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. 57 (1997) 19-25
97. Chen Y., Yu D.C., Charlton D., and Henderson D.R. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene Ther. 11 (2000) 1553-1567
98. Kay M.A., et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24 (2000) 257-261
99. Hacein-Bey-Abina S., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346 (2002) 1185-1193
100. Yla-Herttuala S., and Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med. 9 (2003) 694-701
101. Sellar G.C., et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet. 34 (2003) 337-343
102. Leath III C.A., et al. Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma. Gynecol. Oncol. 94 (2004) 352-362
103. Gopalan B., Litvak A., Sharma S., Mhashilkar A.M., Chada S., and Ramesh R. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res. 65 (2005) 3017-3024
104. Chan J.K., et al. Suppression of ovarian cancer cell tumorigenicity and evasion of cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res. 65 (2005) 3243-3248
105. Wang M., et al. High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Gynecol. Oncol. 71 (1998) 278-287
106. Hirasawa K., Nishikawa S.G., Norman K.L., Alain T., Kossakowska A., and Lee P.W. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 62 (2002) 1696-1701
107. Peng K.W., TenEyck C.J., Galanis E., Kalli K.R., Hartmann L.C., and Russell S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62 (2002) 4656-4662
108. Myers R., et al. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 12 (2005) 593-599
109. Lim H.Y., et al. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. Cancer Gene Ther. 11 (2004) 532-538
110. Rein D.T., et al. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int. J. Cancer 111 (2004) 698-704
111. Ural A.U., et al. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. Gynecol. Oncol. 76 (2000) 305-310
112. Bauerschmitz G.J., et al. The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res. 62 (2002) 1271-1274